XOMA Corporation (XOMA): Price and Financial Metrics
XOMA Price/Volume Stats
| Current price | $25.34 | 52-week high | $27.00 |
| Prev. close | $26.50 | 52-week low | $13.48 |
| Day low | $25.02 | Volume | 10,200 |
| Day high | $26.00 | Avg. volume | 20,442 |
| 50-day MA | $25.00 | Dividend yield | N/A |
| 200-day MA | $19.01 | Market Cap | 294.83M |
XOMA Stock Price Chart Interactive Chart >
XOMA Corporation (XOMA) Company Bio
XOMA Corporation discovers and develops antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company was founded in 1981 and is based in Berkeley, California.
Latest XOMA News From Around the Web
Below are the latest news stories about XOMA CORP that investors may wish to consider to help them evaluate XOMA as an investment opportunity.
XOMA Declares Quarterly Preferred Stock DividendsEMERYVILLE, Calif., Dec. 20, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock: Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) shall receive a cash dividend equal to $0.53906 per share. Holders of depositary shares, each representing 1/1000 of a share of XOMA’s 8.375% Series B |
XOMA Raises up to $140 Million in Non-Dilutive, Non-Recourse Financing from Funds Managed by Blue Owl Capital Backed by VABYSMO® RoyaltiesLow-cost financing capitalizes on XOMA’s $14 million acquisition of VABYSMO® (faricimab) royalties in 2021 Proceeds expected to be used for stock repurchases and additional royalty and milestone acquisitions Financing from Blue Owl extends XOMA’s capabilities as a leading provider of capital to emerging biotech companies EMERYVILLE, Calif., Dec. 19, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, today announced it entered into a non-dilutive, non-recour |
XOMA Reports Third Quarter 2023 Financial Results and Highlights Upcoming Events Expected to Drive Shareholder ValueReceived $6.6 million in cash receipts during the quarter related to our growing royalty base and certain development milestones One New Drug Application (NDA) was filed in the third quarter; another is anticipated prior to year-end Company anticipates the initiation of multiple Phase 3 programs by year-end EMERYVILLE, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), the biotech royalty aggregator, reported its third quarter 2023 financial results and highlighted recent |
XOMA Earns $5 Million Milestone Upon FDA Acceptance of Day One’s Tovorafenib NDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)FDA has granted Priority Review and assigned a PDUFA target action date of April 30, 2024EMERYVILLE, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today it has earned a $5 million milestone related to the U.S. Food and Drug Administration’s (FDA) acceptance of Day One Biopharmaceuticals’ New Drug Application (NDA) for tovorafenib as a monotherapy for relapsed or progressive pediatric low-grade glioma (pLGG). The FDA has grant |
Investing in XOMA (NASDAQ:XOMA) five years ago would have delivered you a 32% gainThe main point of investing for the long term is to make money. But more than that, you probably want to see it rise... |
XOMA Price Returns
| 1-mo | N/A |
| 3-mo | 26.89% |
| 6-mo | 34.93% |
| 1-year | 36.31% |
| 3-year | -33.42% |
| 5-year | 103.86% |
| YTD | 36.97% |
| 2023 | 0.54% |
| 2022 | -11.75% |
| 2021 | -52.75% |
| 2020 | 61.65% |
| 2019 | 115.81% |
Continue Researching XOMA
Want to see what other sources are saying about XOMA Corp's financials and stock price? Try the links below:XOMA Corp (XOMA) Stock Price | Nasdaq
XOMA Corp (XOMA) Stock Quote, History and News - Yahoo Finance
XOMA Corp (XOMA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...